PharmacoEconomics - open

Keyphrases

Publications

2023

Hanna Skrobanski, Kishan Vyas, Sally Bowditch, Lena Hubig, Edward Dziadulewicz, Louise Fish, Pooja Takhar, Siu Hing Lo
The Burden of Caring for Individuals with Tuberous Sclerosis Complex (TSC) Who Experience Epileptic Seizures: A Descriptive UK Survey. PharmacoEconomics - open (2023)
Julie Vanderpoel, Bruno Emond, Isabelle Ghelerter, Katherine Milbers, Marie-Hélène Lafeuille, Patrick Lefebvre, Lorie A Ellis
Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis. PharmacoEconomics - open (2023)
François-Xavier Chalet, Teodora Bujaroska, Evi Germeni, Nizar Ghandri, Emilio T Maddalena, Kushal Modi, Abisola Olopoenia, Jeffrey Thompson, Matteo Togninalli, Andrew H Briggs
Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective. PharmacoEconomics - open (2023)
Jan Heerman, Charlotte Boydens, Silvie Allaert, Koen Cathenis, Koen Deryckere, Henk Vanoverschelde
Effect of Perioperative Oral Vitamin C Supplementation on In-Hospital Postoperative Medication Costs for Cardiac Surgery Patients: A Prospective, Single-Centre, Randomised Clinical Trial. PharmacoEconomics - open (2023)
Rachel Hellen Petra Schreurs, Arina Ten Cate-Hoek, Hugo Ten Cate, Manuela A Joore
Budget Impact of Three Improvement Targets for Compression Therapy for Patients with Deep Venous Thrombosis in The Netherlands. PharmacoEconomics - open (2023)
Charles Yan, Jeff Round, Ilke Akpinar, Chantal E Atwood, Lesly Deuchar, Mohit Bhutani, Richard Leigh, Michael K Stickland
Cost Analysis of a Transition Care Bundle Compared with Usual Care for COPD Patients Being Discharged from Hospital: Evaluation of a Randomized Controlled Trial. PharmacoEconomics - open (2023)
A M Alonso Torres, A G Arévalo Bernabé, N Becerril Ríos, María Fuensanta Hellín Gil, José Manuel Martinez Sesmero, Virginia Meca-Lallana, Lluis Ramio-Torrentà, Alfredo Rodríguez-Antigüedad, L Gómez Maldonado, I Triana Junco, M Gómez-Barrera, Nataly Espinoza-Cámac, Itziar Oyagüez
Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain. PharmacoEconomics - open (2023)
Esra Çakar, César Oniangue-Ndza, Ralph P Schneider, Sven L Klijn, Ursula M Vogl, Christian Rothermundt, Jessica R May
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland. PharmacoEconomics - open (2023)
Taihang Shao, Mingye Zhao, Leyi Liang, Lizheng Shi, Wenxi Tang
Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067. PharmacoEconomics - open (2023)
Andre Verhoek, Parneet Cheema, Barbara Melosky, Benoit Samson, Frances A Shepherd, Filippo de Marinis, Thomas John, Yi-Long Wu, Bart Heeg, Nadia Van Dalfsen, Benjamin Bracke, Miguel Miranda, Simon Shaw, Daniel Moldaver
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer. PharmacoEconomics - open (2023)
Megane Caillon, Benoit Brethon, Chrissy van Beurden-Tan, Romain Supiot, Antoine Le Mezo, Jean-Vannak Chauny, Istvan Majer, Arnaud Petit
Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France. PharmacoEconomics - open (2023)
Eliza Kruger, Daniel Aggio, Hayley de Freitas, Andrew Lloyd
Estimation of Health Utility Scores for Glycogen Storage Disease Type Ia. PharmacoEconomics - open (2023)
Fiona Koster, Marc-Redwart Kok, Jaco van der Kooij, Geeke Waverijn, Angelique Elisabeth Adriana Maria Weel, Deirisa Lopes Barreto
Dealing with Time Estimates in Hospital Cost Accounting: Integrating Fuzzy Logic into Time-Driven Activity-Based Costing. PharmacoEconomics - open (2023)
Claudio Jommi, Carlotta Galeone
The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rajiv Mallick, Rashad Carlton, Joris Van Stiphout
A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States. PharmacoEconomics - open (2023)
Kenar D Jhaveri, Mark E Bensink, Martin Bunke, Jonathon A Briggs, David M W Cork, Anushya Jeyabalan
Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis. PharmacoEconomics - open (2023)
Aaron Winn, Anirban Basu, Scott D Ramsey
A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America. PharmacoEconomics - open (2023)
Eoin Moloney, Atefeh Mashayekhi, Mehdi Javanbakht, Mohsen Rezaei Hemami, Michael Branagan-Harris
Cost-Utility Analysis of the Caresyntax Platform to Identify Patients at Risk of Surgical Site Infection Undergoing Colorectal Surgery. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rajiv Mallick, Rashad Carlton, Joris Van Stiphout
A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States. PharmacoEconomics - open (2023)
Anna Philipson, Anna Duberg, Lars Hagberg, Sofie Högström, Lars Lindholm, Margareta Möller, Linda Ryen
The Cost-Effectiveness of a Dance and Yoga Intervention for Girls with Functional Abdominal Pain Disorders. PharmacoEconomics - open (2023)
Rajiv Mallick, Rashad Carlton, Joris Van Stiphout
A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States. PharmacoEconomics - open (2023)
Evans Otieku, Ama Pokuaa Fenny, Appiah-Korang Labi, Alex Owusu Ofori, Joergen Anders Lindholm Kurtzhals, Ulrika Enemark
Attributable Patient Cost of Antimicrobial Resistance: A Prospective Parallel Cohort Study in Two Public Teaching Hospitals in Ghana. PharmacoEconomics - open (2023)
Owen Alan Edwards Cooper, Ola Ghatnekar, Natalia Piglowska, Charlie A Smith, Paul Swinburn, James W F Catto, Günter Niegisch, Jørn Skibsted Jakobsen
Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC). PharmacoEconomics - open (2023)
Aryana Sepassi, Ila M Saunders, Mark Bounthavong, Randy A Taplitz, Cathy Logan, Jonathan H Watanabe
Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States. PharmacoEconomics - open (2023)
Shanlian Hu, Zhiliu Tang, James P Harrison, Nadine Hertel, John R Penrod, Jessica R May, Ariadna Juarez-Garcia, Orban Holdgate
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China. PharmacoEconomics - open (2023)
Christopher Skedgel, Patricia Cubi-Molla, David Mott, Sofia Gameiro, Jacky Boivin, Hareth Al-Janabi, John Brazier, Marie Markert, Fredrik L Andersson, Mireia Jofre-Bonet
Unmet Parenthood Goals, Health-Related Quality of Life and Apparent Irrationality: Understanding the Value of Treatments for Infertility. PharmacoEconomics - open (2023)
Tiziana Magni, Chiara Ragni, Nicola Pelizzi, Sheetal Sharma, Lucia Perez-Kempner, Erika Turkstra, Jyothsna Nathani, Martina Orlovic, Natalia Meshchenkova
Health Economic Studies of Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome: A Systematic Literature Review. PharmacoEconomics - open (2023)
Amy Dymond, Will Green, Mary Edwards, Maria Angeles Lopez Pont, Girish Gupta
Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland. PharmacoEconomics - open (2023)
Fiona Koster, Marc-Redwart Kok, Jaco van der Kooij, Geeke Waverijn, Angelique Elisabeth Adriana Maria Weel, Deirisa Lopes Barreto
Dealing with Time Estimates in Hospital Cost Accounting: Integrating Fuzzy Logic into Time-Driven Activity-Based Costing. PharmacoEconomics - open (2023)
Evans Otieku, Ama Pokuaa Fenny, Appiah-Korang Labi, Alex Owusu Ofori, Joergen Anders Lindholm Kurtzhals, Ulrika Enemark
Attributable Patient Cost of Antimicrobial Resistance: A Prospective Parallel Cohort Study in Two Public Teaching Hospitals in Ghana. PharmacoEconomics - open (2023)
François-Xavier Chalet, Teodora Bujaroska, Evi Germeni, Nizar Ghandri, Emilio T Maddalena, Kushal Modi, Abisola Olopoenia, Jeffrey Thompson, Matteo Togninalli, Andrew H Briggs
Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective. PharmacoEconomics - open (2023)
John Jacob, Chelsea Stunden, Dhayanand Deenadayalan, Luke Thomas
Economic Evaluation Comparing Virtual Reality with Child Life Programming for Non-sedated Pediatric Medical Imaging: A Cost-Consequence Analysis. PharmacoEconomics - open (2023)
Rajiv Mallick, Rashad Carlton, Joris Van Stiphout
A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States. PharmacoEconomics - open (2023)
Hiral Anil Shah, Tim Baker, Carl Otto Schell, August Kuwawenaruwa, Khamis Awadh, Karima Khalid, Angela Kairu, Vincent Were, Edwine W Barasa, Peter Baker, Lorna Guinness
Cost Effectiveness of Strategies for Caring for Critically Ill Patients with COVID-19 in Tanzania. PharmacoEconomics - open (2023)
Christopher Skedgel, Patricia Cubi-Molla, David Mott, Sofia Gameiro, Jacky Boivin, Hareth Al-Janabi, John Brazier, Marie Markert, Fredrik L Andersson, Mireia Jofre-Bonet
Unmet Parenthood Goals, Health-Related Quality of Life and Apparent Irrationality: Understanding the Value of Treatments for Infertility. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Hiral Anil Shah, Tim Baker, Carl Otto Schell, August Kuwawenaruwa, Khamis Awadh, Karima Khalid, Angela Kairu, Vincent Were, Edwine W Barasa, Peter Baker, Lorna Guinness
Cost Effectiveness of Strategies for Caring for Critically Ill Patients with COVID-19 in Tanzania. PharmacoEconomics - open (2023)
Ryan Pulleyblank, Nikolaj Birk Larsen
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Mackenzie Mills, Panos Kanavos
Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries. PharmacoEconomics - open (2023)
Paolo Angelo Cortesi, Carla Fornari, Paolo Gisondi, Florenzo Iannone, Ippazio Cosimo Antonazzo, Elisabetta Aloisi, Martina Fiocchi, Daniela Ritrovato, Lorenzo Giovanni Mantovani
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy. PharmacoEconomics - open (2023)
Owen Alan Edwards Cooper, Ola Ghatnekar, Natalia Piglowska, Charlie A Smith, Paul Swinburn, James W F Catto, Günter Niegisch, Jørn Skibsted Jakobsen
Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC). PharmacoEconomics - open (2023)

volume 7, number 1, 2023

François-Xavier Chalet, Teodora Bujaroska, Evi Germeni, Nizar Ghandri, Emilio T Maddalena, Kushal Modi, Abisola Olopoenia, Jeffrey Thompson, Matteo Togninalli, Andrew H Briggs
Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective. PharmacoEconomics - open 7 (1) (2023)
François-Xavier Chalet, Teodora Bujaroska, Evi Germeni, Nizar Ghandri, Emilio T Maddalena, Kushal Modi, Abisola Olopoenia, Jeffrey Thompson, Matteo Togninalli, Andrew H Briggs
Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective. PharmacoEconomics - open 7 (1) (2023)
François-Xavier Chalet, Teodora Bujaroska, Evi Germeni, Nizar Ghandri, Emilio T Maddalena, Kushal Modi, Abisola Olopoenia, Jeffrey Thompson, Matteo Togninalli, Andrew H Briggs
Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective. PharmacoEconomics - open 7 (1) (2023)

volume 7, number 3, 2023